Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Study phase: II
Study phase (if other): III
Primary disease category: Cancer
Secondary disease categories: Cancer, Lung Cancer
Sponsor: Southwest Oncology Group
Protocol number: S1400
Projected enrollment dates: June 2015 to April 2022
Official study title: S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT02154490